FAU and Hydron Release Wound Healing Cell Study Results

FAU and Hydron Release Wound Healing Cell Study Results 


POMPANO BEACH, Fla., Nov. 21  /PRNewswire-FirstCall/ -- Scientists at Florida
Atlantic University and Hydron Technologies, Inc.  (BULLETIN BOARD: HTEC) 
released findings that skin cells exposed to a new technology created by Hydron
using oxygenated microbubbles showed significant increases in the production of
proteins, which help in stimulating wound healing.

"Hydron has made another major step forward with this research," said Terrence
McGrath, Hydron's Chief Operating Officer. "By examining the effects of tissue
oxygenation at the cellular level, Hydron is establishing that delivering high
levels of oxygen through microbubble-laden fluids can positively affect medical
treatments for wounds, burns and numerous other skin conditions."

Two studies were conducted in FAU's Charles E. Schmidt College of Science,
Biomedical Sciences department by Drs. Peter Lutz and Howard Prentice who are
recognized experts on cells in low oxygen environments. The first study was
designed to determine cell viability when exposed to Hydron's super-oxygenated
fluids. In the report, they recorded that when skin cells were cultured in the
presence or absence of oxygenated microbubbles, oxygenated microbubble exposure
had no toxic or negative effect on cell survival.

In the second study, the investigators also carried out an investigation on
levels of specialized proteins called HSPs which are induced in cells under a
wide variety of stress conditions and are important for cell survival in many
clinical disorders. In studies on wound healing, it has been found that these
specialized proteins at the site of wounds improve healing.  The study showed
that using oxygen-laden microbubbles, increased the HSP levels in the skin
cells.  When combined with the findings of the cell viability study, it is
determined that Hydron's technology encourages cell survival.

"This is exactly the type of relationship that is important to foster for both
FAU and our regional industries," said Kevin Petrovsky, director of development
for the Charles E. Schmidt College of Science.  "The outstanding research
faculty, graduate students and laboratory facilities in the College play a vital
role in the growth and development of south Florida's biotechnology, biomedical
and other scientific industries.  We will continue to foster regional and
national partnerships that support companies, further scientific discovery and
define south Florida as a world-class research destination."

The studies are considered a catalyst for additional cellular-level research and
will establish parameters on new products and treatments, according to Hydron.
The company has recently concluded a private placement financing to accelerate
its research program and development of viable products.

Hydron Technologies, Inc. markets a broad range of personal care products and is
committed to the research and development of products and medical applications
associated with its proprietary tissue oxygenation technology. The Company
markets its skin care products through Hydron's direct-to-consumer catalog and
on the Internet at http://www.hydron.com/. Catalogs are available by calling
1-800-4-HYDRON (1-800-449-3766).  Except for historical information, all of the
expectations and assumptions contained in the foregoing are forward-looking
statements involving risks and uncertainties. For additional information
regarding the risks associated with the Company's business, refer to Hydron
Technologies, Inc. reports filed with the SEC. 

DATASOURCE: Hydron Technologies, Inc.



CONTACT:  Terrence S. McGrath, Chief Operating Officer, Hydron

Technologies, Inc., [phone], or ; or Aileen

Izquierdo, Director of Media Relations, Florida Atlantic University,

[phone], or 



Web site:  http://www.hydron.com/

Copyright